A 6-Month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents with Tourette's Disorder (TD)

ID Number 13-1234

Principal Investigator(s)
Barbara Coffey

Department(s) or Division(s)


The objectives of this study are to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of AZD5213 in adolescents with Tourette's Disorder (TD). Currently the only approved medications for TD are the classic neuroleptics haloperidol and pimozide. Although many other medications are used off-label for the treatment of TD, including other antipsychotics and alpha-agonists, none are clearly effective and all carry significant side effects. AZD5213 is a novel histamine H3 receptor inverse agonist that shows promise for the potential treatment of a variety of indications, including TD.

Currently closed to enrollment.

Contact Information
Laura Ibanez
(212) 659-1676

Recruiting Patients: No